Fig. 1 · Structure

Documents & Downloads

Doramapimod (BIRB-796)

Cat. No. A10148 CAS 285983-48-4

p38 MAPK inhibitor

Doramapimod (BIRB 796) is a small molecule inhibitor of p38 MAPK,which plays a critical role in regulating the production of proinflammatory cytokines.

In Stock

Publications for Doramapimod

4 publications citing this product

  1. Vincent de Laat, .et al. , Nat Commun, 2024, Oct 2;15(1):8540 PMID: 39358362
  2. Ken Kobayashi, .et al. , Cell Tissue Res, 2022, Sep;389(3):501-515 PMID: 35748981
  3. Junsuke Uwada, .et al. , Biochem Pharmacol, 2020, Oct 22;182:114297 PMID: 33132165
  4. Perera LMB, .et al. , J Invest Dermatol, 2018, Nov 4. pii: S0022-202X(18)32791-X PMID: 30404019

Free Aliquoting for Your Order

Tell us your preferred amount per vial. We’ll confirm the options.

Biological Activity

Bioactivity / Mechanism

Doramapimod (BIRB-796) binds p38 MAP kinase in the DFG-out conformation, engaging an allosteric pocket and the ATP-site region. Fluorescence competition experiments reported a binding Kd of 0.1 nM and slow dissociation. This binding affinity is distinct from a cellular IC50. [1]

Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.

Target & Activity

Target Activity Value
p38α (Cell-free assay) Kd 0.1 nM
p38α 38 nM

Cellular Effect

Cell Line Activity Value Description Reference
PBMC IC50 15 nM Antiinflammatory activity in LPS-stimulated human isolated PBMC assessed as inhibition of TNFalpha production preincubated for 1 hr prior to LPS-challenge by ELISA [PMID: 21888439]
PBMC IC50 30 nM Inhibition of LPS-stimulated TNFalpha release in human PBMC by ELISA [PMID: 18602262]
U-937 IC50 15 nM Antiinflammatory activity in differentiated human U937 cells assessed as inhibition of LPS-induced TNFalpha production preincubated for 2 hrs followed by LPS-stimulation for 4 hrs by sandwich ELISA relative to vehicle-treated control [PMID: 26800309]

Doramapimod (BIRB-796) Research Summary

This section summarizes 3 in vitro studies and 1 in vivo study of Doramapimod (BIRB-796) from 2 published references. In vitro models include human p38 MAP kinase–BIRB796 co-crystal; purified human p38 MAP kinase.

Doramapimod (BIRB-796) In Vitro Studies

In LPS-stimulated human THP-1 cells, BIRB-796 inhibited TNFα release with a reported IC50 of 18 ± 3 nM. The paper does not define the ± statistic for this endpoint. [1]

Allosteric binding conformation

Biochemical assay · Human p38 MAP kinase–BIRB796 co-crystal [1]

The BIRB796 complex adopts the DFG-out conformation and contacts an allosteric pocket as well as the ATP-site region.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
BIRB796 co-crystal diffraction resolutionresolution 2.8 Å[1]

Literature-Reported Treatment Conditions

Method
Co-crystal structure determination; comparison with compound 1 and earlier ATP-site structures.
Reported limits
Compound purity and salt specification were not provided in the read main text.
Methods and source locations

Compound reported in the paper: Doramapimod (BIRB-796); Compound label in the paper: BIRB 796

Evidence concerns the reported research material; no Adooq lot equivalence or salt conversion is established.

p.269, Figure 3c and BIRB 796 structural section; p.271, Table 1 and crystallographic Methods

BIRB796 co-crystal diffraction resolution: X-ray crystallography — p.269 structural Results; p.271 Table 1

Slow binding to p38 MAP kinase

Biochemical assay · Purified human p38 MAP kinase [1]

BIRB796 showed slow association and dissociation in fluorescence competition experiments.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Binding affinity calculated as koff/kon at 23 °CKd 0.1 nM[1]
BIRB796 dissociation rate constantkoff 8.3 × 10^-6 ± 1.5 × 10^-7 s^-1[1]

Literature-Reported Treatment Conditions

Treatment concentration
Figure 4c: 174 nM kinase and 290 nM BIRB796.
Exposure duration
BIRB796 half-reaction preincubation: 60 min; fluoroprobe half-reaction: 3 min.
Method
Exchange curves fitted to simple competitive binding.
Reported limits
Figure 1 does not define the ± statistic or replicate count; no uncertainty type is assigned.
Methods and source locations

Compound reported in the paper: Doramapimod (BIRB-796); Compound label in the paper: BIRB 796

Evidence concerns the reported research material; no Adooq lot equivalence or salt conversion is established.

p.268 Figure 1; p.270 Figure 4c and kinetic Results; p.271 Binding studies

Binding affinity calculated as koff/kon at 23 °C: Competitive fluorescence binding using SK&F 86002 — p.268 Figure 1 and caption

BIRB796 dissociation rate constant: Simultaneous fitting of exchange-curve half-reactions — p.268 Figure 1; p.271 Binding studies

Inhibition of THP-1 TNFα release

Cell-based study · Human THP.1 cells stimulated with LPS [1]

BIRB796 inhibited released TNFα in a cellular ELISA assay.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Inhibition of LPS-induced TNFα releaseIC50 18 ± 3 nM[1]

Literature-Reported Treatment Conditions

Method
LPS-stimulated THP.1 assay; released TNFα quantified by commercial ELISA.
Co-treatment
LPS stimulation; no second inhibitor combination adopted.
Reported limits
Read main text does not specify drug exposure duration, vehicle, tested concentration range, replicate count or meaning of ± for this endpoint.
Methods and source locations

Compound reported in the paper: Doramapimod (BIRB-796); Compound label in the paper: BIRB 796

Evidence concerns the reported research material; no Adooq lot equivalence or salt conversion is established.

p.268 Figure 1; p.271 cellular Methods

Inhibition of LPS-induced TNFα release: TNFα ELISA, with compound-present and compound-absent conditions — p.268 Figure 1; p.271 cellular Methods

Doramapimod (BIRB-796) In Vivo Studies

In Ang II-infused C57Bl/6J mice, oral BIRB796 at 50 mg/kg/day reduced Week 2 systolic blood pressure to 155 ± 3 mmHg versus 173 ± 3 mmHg with vehicle (mean ± SEM; n = 8 per group). Treatment began 2 days before infusion. Blood pressure did not normalize. [2]

Oral BIRB796 in Ang II-dependent hypertension

Animal study · 12-week-old C57Bl/6J mice; Ang II infusion at 1000 ng/kg BW/min for 14 days [2]

Oral BIRB796 attenuated the systolic blood pressure increase without normalizing it.

Measured endpoints — not treatment concentrations
EndpointReported resultReference
Systolic blood pressure at Week 2mean ± SEM Vehicle: 173 ± 3 mmHg; BIRB796: 155 ± 3 mmHg; n = 8 per group; p < 0.001[2]

Conditions shared by the study groups

Route
Oral, in mouse chow
Frequency
Daily intake via chow
Treatment course
Started 2 days before Ang II infusion; continued during the 14-day observation period.
Vehicle
Mouse chow
Study groups and reported outcomes
Group / doseComparatorObserved resultReference
Ang II + BIRB796
50 mg/kg BW/d
Ang II plus vehicle chow; Figure 1a: n = 8 per group.Week 2 systolic blood pressure: 155 ± 3 versus 173 ± 3 mmHg (BIRB796 versus vehicle), mean ± SEM; p < 0.001 in caption text. Blood pressure remained elevated.[2]
Ang II + BIRB796
Model: 12-week-old C57Bl/6J mice; Ang II infusion at 1000 ng/kg BW/min for 14 days
Reported limits: Sex and achieved drug exposure were not specified in the read animal treatment section.
Methods and source locations

Compound reported in the paper: Doramapimod (BIRB-796); Compound label in the paper: BIRB 796

Evidence concerns the reported research material; no Adooq lot equivalence or salt conversion is established.

Animal treatment; Systolic blood pressure measurement; Figure 1a/caption; Statistics; Discussion

Systolic blood pressure at Week 2: Daily noninvasive tail-cuff measurements summarized by week — Figure 1a and caption; Systolic blood pressure measurement; Statistics

Ang II + BIRB796 · Animal care/treatment; Systolic blood pressure measurement; Figure 1a/caption; Discussion

Specifications

Manufacturer Adooq Bioscience
Actions Inhibitor
CAS Number 285983-48-4
Applications p38 MAPK inhibitor
Formula C31H37N5O3
Molecular Weight 527.7
Synonyms BIRB-796
SMILES
CC1=CC=C(C=C1)N2C(=CC(=N2)C(C)(C)C)NC(=O)NC3=CC=C(C4=CC=CC=C43)OCCN5CCOCC5

Storage & Solubility

In Vitro Solubility

Reported Solubility

SolventReported Solubility
DMSO 99 mg/mL (187.61 mM)
Water Insoluble
Ethanol 99 mg/mL (187.61 mM)

Preparing Stock Solutions

Stock preparation is unavailable for this product molecular weight.

Calculated stock concentrations do not establish solvent solubility. Refer to the reported solubility data for experimental guidance.

In Vivo Preparation

Concentration
4 mg/mL
Vehicle
5% DMSO+40%PEG300+5%Tween80??+50%H2O

Storage

Store powder at -20°C, keep desiccated.
In powder form, the chemical is stable for 36 months.
In solution, store at -20°C and use within 1 month to prevent loss of potency. Aliquot to avoid multiple freeze/thaw cycles.

Doramapimod (BIRB-796) Research References

  1. [1] Christopher Pargellis, Liang Tong, Laurie Churchill, et al. Inhibition of p38 MAP kinase by utilizing a novel allosteric binding site Nature Structural Biology (2002). PMID: 11896401 DOI: 10.1038/nsb770 Source material
  2. [2] SA Potthoff, S Stamer, K Grave, et al. Chronic p38 mitogen-activated protein kinase inhibition improves vascular function and remodeling in angiotensin II-dependent hypertension Journal of the Renin-Angiotensin-Aldosterone System (2016). PMID: 27407119 DOI: 10.1177/1470320316653284 Source material

Publications

4 publications citing this product

  1. Vincent de Laat, .et al. , Nat Commun, 2024, Oct 2;15(1):8540 PMID: 39358362
  2. Ken Kobayashi, .et al. , Cell Tissue Res, 2022, Sep;389(3):501-515 PMID: 35748981
  3. Junsuke Uwada, .et al. , Biochem Pharmacol, 2020, Oct 22;182:114297 PMID: 33132165
  4. Perera LMB, .et al. , J Invest Dermatol, 2018, Nov 4. pii: S0022-202X(18)32791-X PMID: 30404019

Added to your cart

View Cart Checkout
Loading...